Last updated: 11/07/2018 05:34:56
Adherence Benefits in Tx Enlarged Prostate:Medstat
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Value of Early 5-alpha-reductase Inhibitor (5ARI) Treatment in Patients Receiving Combination 5ARI and Alpha-Blocker (AB) Therapy for Enlarged Prostate (EP)
Trial description: GHO-09-0244: Value Value of Early 5-alpha-reductase Inhibitor (5ARI) Treatment in Patients Receiving Combination 5ARI and Alpha-Blocker (AB) Therapy for Enlarged Prostate (EP) A MarketScan Database Assessment
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
To assess the proportion of patients with clinical progression (defined as acute urinary retention [AUR] or prostate-related surgery) in those receiving combination therapy (5ARI + AB) with early vs late 5ARI initiation.
Timeframe: Within the defined study period, claims will be assessed for a 7-month time period, beginning after a 5-month outcomes exclusionary peri-period from the date of the first prescription claim for an AB.
Secondary outcomes:
To assess the medical costs in patients receiving combination therapy (5ARI + AB) with early vs late 5ARI initiation.
Timeframe: Within the defined study period, medical costs will be assessed for a 7-month time period, beginning after a 5-month outcomes exclusionary peri-period from the date of the first prescription claim for an AB.
To assess the pharmacy costs in patients receiving combination therapy (5ARI + AB) with early vs late 5ARI initiation.
Timeframe: Within the defined study period, pharmacy costs will be assessed for the entire 1-year follow-up period from the date of the first prescription claim for an AB.
Interventions:
Drug: 5ARI + AB
Enrollment:
0
Observational study model:
Cohort
Primary completion date:
Not applicable
Time perspective:
Other
Clinical publications:
Eric J. Kruep, Susan L. Hogue, Michael T. Eaddy, Monica D. Chandra. Clinical and Economic Impact of Early versus Delayed 5a-reductase Inhibitor Therapy in Men on Alpha Blockers for Symptomatic Benign Prostatic Hyperplasia . [P & T]. 2011;36(8):493-507.
Medical condition
Prostatic Hyperplasia
Product
dutasteride
Collaborators
Not applicable
Study date(s)
March 2009 to August 2009
Type
Observational
Phase
4
Participation criteria
Sex
Male
Age
50+ years
Accepts healthy volunteers
none
- Male patients aged 50 years or older with a medical claim of enlarged prostate and prescription claims for both an AB and 5ARI (5ARI claim must be within 6 months of initiating an AB). Patients were required to be continuously eligible for 6 months prior to and at least 12 months after index prescription date.
- Patients with prostate or bladder cancer; any prostate-related surgical procedure or any surgical procedure prior to the index prescription date and in the 5 month peri-period; prescription claim for finasteride indicative of male pattern baldness
Inclusion and exclusion criteria
Inclusion criteria:
- Male patients aged 50 years or older with a medical claim of enlarged prostate and prescription claims for both an AB and 5ARI (5ARI claim must be within 6 months of initiating an AB). Patients were required to be continuously eligible for 6 months prior to and at least 12 months after index prescription date.
Exclusion criteria:
- Patients with prostate or bladder cancer; any prostate-related surgical procedure or any surgical procedure prior to the index prescription date and in the 5 month peri-period; prescription claim for finasteride indicative of male pattern baldness
Trial location(s)
No location data available.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
Not applicable
Actual study completion date
2009-20-08
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website